Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.

H.C. Wainwright Global Investment Conference
Format: Pre-recorded presentation and one-on-one investor meetings
Date: Tuesday, May 24, 2022
Time: Presentation available at 7:00 a.m. ET
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit

For Investors:
Bruce Mackle
LifeSci Advisors, LLC

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC

error: Content is protected !!